1. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). (29th January 2019) Authors: Ghesquieres, H; Chevrier, M; Laadhari, M; Chinot, O; Choquet, S; Moluçon-Chabrot, C; Beauchesne, P; Gressin, R; Morschhauser, F; Schmitt, A; Gyan, E; Hoang-Xuan, K; Nicolas-Virelizier, E; Cassoux, N; Touitou, V; Le Garff-Tavernier, M; Savignoni, A; Turbiez, I; Soumelis, V; Houillier, C Journal: Annals of oncology Issue: Volume 30:Number 4(2019) Page Start: 621 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. S7A:8 Efficacy and safety of ustekinumab, an interleukin 12/23 inhibitor, in patients with active systemic lupus erythematosus: results of a phase 2, randomised placebo-controlled study. (21st March 2018) Authors: van Vollenhoven, R; Hahn, B; Tsokos, G; Wagner, C; Lipsky, P; Hsu, B; Chevrier, M; Gordon, R; Triebel, M; Rose, S Journal: Lupus science & medicine Issue: Volume 5(2018)Supplement 1 Page Start: A28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗